Replies to post #94013 on Biotech Values

[DewDiligence]

Data from GILD’s two phase-3 trials of Quad* vs Atripla and Quad vs Truvada+Reyataz will be available in 3Q11 and 4Q11, respectively, according to GILD’s 3Q10 CC today.

*Quad is a 4-drug combination pill consisting of Viread, Emtriva, Elvitegravir, and Cobicistat (GILD’s proprietary PK-boosting agent).